|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma显示文摘 | A. K.Singal D. H.Freeman Jr B. S.Anand | 2010 | Alimentary Pharmacology & Therapeutics2010，，7： | 1 |
| 2 | The renal safety of bowel preparations for colonoscopy: a comparative study of oral sodium phosphate solution and polyethylene glycol显示文摘 | A. K.SINGAL A. S.ROSMAN J. B.POST W. A.BAUMAN A. M.SPUNGEN M. A.KORSTEN | 2007 | Alimentary Pharmacology & Therapeutics2007，，1： | 1 |
| 3 | Sending an SOS: Healing the Liver with the Bone Marrow显示文摘Citation of this article:Ayares G,Arab JP,Singal AK.Sending an SOS:Healing the Liver with the Bone Marrow.J Clin Transl Hepatol 2022;10(1):1-3.doi:10.14218/JCTH.2021.00557.Cirrhosis,an end stage of any chronic liver disease is a form of impaired regeneration leading to progressive dif-fuse hepatic fibrosis.The healthcare burden of cirrhosis is increasing,and it is currently the 13th leading cause of death globally.The progression of liver injury and fibrosis results in portal hypertension and hepatic insufficiency. | Gustavo Ayares Juan Pablo Arab Ashwani K.Singal | 2022 | Journal of Clinical and Translational Hepatology2022，10，1： | 0 |
| 4 | 入院时血氨水平可预测酒精性肝炎患者的住院病死率显示文摘目的:酒精性肝炎(AH)是慢性或急性饮酒者一种特有的临床综合征,具有较高的短期死亡率。在急性肝衰竭患者中,血氨浓度升高者病死率增高;然而,其对AH患者的影响尚不明确。方法:在一家三甲医院中,对出院诊断为AH的患者进行回顾性分析。将满足AH诊断标准的病例纳入最终的数据分析。建立多因素逻辑回归模型用以评估血氨水平对住院病死率和30天病死率的预测价值。并对其中的肝性脑病患者进行亚组分析。结果:在105例纳入研究的AH患者中,26例(25%)在首次住院期间死亡。在79例出院患者中,30例(39%)于30天内死亡。82例患者入院时进行了血氨检测,其中,住院期间死亡的25例患者血氨水平明显增高(97 vs.69μmol/L,P<0.01)。而在57例出院患者中,30天内死亡与未死亡病例血氨水平的差异无统计学意义(71 vs.67μmol/L,P=0.69)。将血氨水平加入包括年龄、性别、肝硬化、治疗方式、终末期肝病模型(MELD)评分的多因素回归模型后,模型预测住院病死率的C值由0.708显著提高至0.801,预测术后30天病死率的C值则由0.756轻微升高至0.766。针对肝性脑病患者进行亚组分析,亦得到了类似的结果。结论:AH患者入院时血氨水平升高,其住院死亡风险增加;而当患者顺利出院后,血氨水平升高似乎并不会影响30天病死率。 | Sujan Ravi Kaely S.Bade Mohsen Hasanin Ashwani K.Singal | 2017 | Gastroenterology Report2017，5，3： | 0 |
| 5 | Integrated Multidisciplinary Management of Alcoholassociated Liver Disease显示文摘Alcohol-associated liver disease(ALD)is one of the most common liver diseases and indications for liver transplantation(LT).Alcohol use disorder(AUD),a frequent accompaniment in ALD patients,may also be associated with psychiatric comorbidities such as depression and anxiety.Identification of ALD at an earlier stage,and treatment of AUD may help prevent progression to advanced stage of ALD such as cirrhosis and alcoholic hepatitis.Screening for alcohol use and AUD treatment in ALD patients is often not performed due to several barriers at the level of patients,clinicians,and administrative levels.This review details the integrated multidisciplinary care model especially on the specific role of the hepatologist,psychiatrist,addiction counselor,and social worker in providing complete management for the dual pathology of liver disease and of AUD.Laboratory assessment,pharmacological and behavioral therapies,and recommended assessments for follow-up care by the respective specialists is outlined.We provide perspective along with the literature support,with the goal of providing team based comprehensive care of patients with ALD. | Malia Holbeck Hannah Statz DeVries Ashwani K.Singal | 2023 | Journal of Clinical and Translational Hepatology2023，11，6： | 0 |
| 6 | Mitochondrial dysfunction and alcohol-associated liver disease:a novel pathway and therapeutic target显示文摘In a recent study in signal transduction and targeted therapy,Zhou et al.provided novel experimental data on the role of DNAdependent protein kinase catalytic subunit(DNA-PKcs)in causing abnormalities in the structure and function of mitochondria of hepatocytes,leading to liver injury and alcohol-associated liver disease(ALD). | Mohamed A.Abdallah Ashwani K.Singal | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 0 |
| 7 | Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA显示文摘Background and Aims:Alcohol-associated liver disease(ALD)is the most common cause of advanced liver disease worldwide,including in the USA.Alcohol use and cirrhosis mortality is higher in American Indian/Alaska Native(AI/AN)compared to Whites.Data are scanty on ALD as a liver disease etiology in AI/AN compared to other races and ethnicities.Methods:The National Inpatient Sample on 199,748 cirrhosis-related hospitalizations,14,241(2,893 AI/AN,2,893 Whites,2,882 Blacks,2,879 Hispanics,and 2,694 Asians or other races)matched 1:1 for race/ethnicity on demographics,insurance,and income quartile of the residence zip code analyzed.Results:After controlling for geographic location and hospital type,odds ratio(OR)and 95%confidence interval(CI)for ALD as cirrhosis etiology was higher among admissions in AI/AN vs.Whites[1.55(1.37–1.75)],vs.Blacks[1.87(1.65–2.11)],vs.Hispanic[1.89(1.68–2.13)]and Asians/other races[2.24(1.98–2.53)].OR was also higher for AI/AN vs.all other races for alcohol-associated hepatitis(AH)as one of the discharge diagnoses.The findings were similar in a subgroup of 4,649 admissions with decompensated cirrhosis and in a cohort of 350 admissions with acute-on-chronic liver failure as defined by EASL-CLIF criteria.Alcohol use disorder diagnosis was present in 38%of admissions in AI/AN vs.24–30%in other races,p<0.001.A total of 838(5.9%)admissions were associated with in-hospital mortality.OR(95%CI)for in-hospital mortality in AI/AN individuals was 34%reduced vs.Blacks[0.66(0.51–0.84)],but no difference was observed on comparison with other races.Conclusions:ALD,including AH,is the most common etiology among cirrhosisrelated hospitalizations in the USA among AI/AN individuals.In-hospital mortality was observed in about 6%of admissions,which was higher for Blacks and similar in other races compared to admissions for AI/AN.Public health policies should be implemented to reduce the burden of advanced ALD among AI/AN individuals. | Ashwani K.Singal Yong-Fang Kuo Juan P.Arab Ramon Bataller | 2022 | Journal of Clinical and Translational Hepatology2022，10，3： | 0 |
| 8 | Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications显示文摘Background and Aims:The COVID-19 pandemic has impacted the care of patients with liver disease.We examined impact of COVID-19 on liver transplant(LT)activity in the USA.Methods:LT listings in the United Network for Organ Sharing(UNOS)database(April 2018–May 2021)were analyzed to examine the impact of COVID-19 pandemic on the LT activity based on etiology:hepatitis C virus(HCV),alcohol-associated liver disease(ALD),alcoholic hepatitis(AH),and nonalcoholic steatohepatitis(NASH)complications:hepatocellular carcinoma(HCC)and acute-on-chronic liver failure(ACLF)grade 2 or 3 and Model for End-Stage Liver Disease(MELD)score.Joinpoint regression models assessed time trend changes on a log scale.Results:Of 23,871 recipients(8,995 in the COVID era,April 2018–February 2020),mean age 52 years,62% men,61% Caucasian,32%ALD,15%HCC,30%ACLF grades 2–3,and mean MELD score 20.5,monthly LT changes were a decrease of 3.4%for overall LTs and 22%for HCC after September 2020,and increase of 4.5%for ALD since 11/2020 and 17%since 03/2021 for ACLF grade 2–3.Monthly MELD scores increased by 0.7 and 0.36 after June 2020 for HCV and HCC respectively.Conclusions:The COVID-19 pandemic has impacted LT activity,with a decrease of LTs especially for HCC,and an increase of LTs for ALD and severe ACLF.Strategies are needed to reorganize cirrhosis patients to overcome the aftereffects of COVID-19 pandemic. | Yong-Fang Kuo Paul Kwo Robert J Wong Ashwani K.Singal | 2023 | Journal of Clinical and Translational Hepatology2023，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员